Yüklüyor......
KRAS G12C Mutations in NSCLC: From Target to Resistance
SIMPLE SUMMARY: A better understanding of the role of KRAS and its different mutations has led to the development of specific small-molecule inhibitors able to target KRAS G12C, an oncogenic driver mutation in a number of cancers, including non-small cell lung cancer. While these therapies hold grea...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8196854/ https://ncbi.nlm.nih.gov/pubmed/34064232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112541 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|